Vice President, Global Research

• Mar 2023 - Present

Vice President, Nonclinical Development

• Jan 2022 - Present

Executive Director, Head of Preclinical DMPK and Toxicology

• Apr 2021 - Jan 2022

Executive Director, Head of Toxicology & DMPK

• Jun 2019 - Apr 2021

Senior Director, Head of Toxicology/DMPK

• May 2017 - May 2019

• Oversee pharmacology/Toxicology/DMPK/Clinical Pharmacology functions responsible for multiple early and late clinical stage drug development projects including plan development and execution • Recruit, train and mentor nonclinical personnel • Oversee pharmacology/Toxicology/DMPK/Clinical Pharmacology functions responsible for multiple early and late clinical stage drug development projects including plan development and execution • Recruit, train and mentor nonclinical personnel

Principal Scientist

• Jul 2013 - May 2017

• Accountable for two late stage development program • Wrote and reviewed regulatory submission in one NDA • Managed safety pharmacology and toxicology studies supporting early discovery and late stage drug candidates • Accountable for two late stage development program • Wrote and reviewed regulatory submission in one NDA • Managed safety pharmacology and toxicology studies supporting early discovery and late stage drug candidates

Principal Scientist

• Sep 2001 - Apr 2013

• Accountable for drug development programs covering multiple therapeutic areas • Managed/conducted safety pharmacology and toxicology studies supporting early discovery and late stage drug candidates • Led a high-performance investigative toxicology team • Accountable for drug development programs covering multiple therapeutic areas • Managed/conducted safety pharmacology and toxicology studies supporting early discovery and late stage drug candidates • Led a high-performance investigative toxicology team

Research Scientist

• Jun 2000 - Aug 2001

- Developed/validated novel immunoassays and DNA based assays using a proprietary technology called the Rolling Circle Amplification Technology (RCAT) with multiplex capability for various applications - Automated in vitro assays - Modified antibody structure in vitro to improve the sensitivity and specificity of an immunoassay - Developed/validated novel immunoassays and DNA based assays using a proprietary technology called the Rolling Circle Amplification Technology (RCAT) with multiplex capability for various applications - Automated in vitro assays - Modified antibody structure in vitro to improve the sensitivity and specificity of an immunoassay

Research Scientist

• Mar 1993 - Dec 1994

- Designed/validated/conducted immunoassays for human HCV viral detection from human blood samples - Expressed/produced/purified viral proteins in bacterial and yeast expression system in a large quantity - Designed/validated/conducted immunoassays for human HCV viral detection from human blood samples - Expressed/produced/purified viral proteins in bacterial and yeast expression system in a large quantity